Does the media refer more to TRDA or ALVO?

In the previous week, Alvotech had 6 more articles in the media than Entrada Therapeutics. MarketBeat recorded 12 mentions for Alvotech and 6 mentions for Entrada Therapeutics. Alvotech's average media sentiment score of 0.84 beat Entrada Therapeutics' score of 0.49 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KURA or TRDA?

In the previous week, Kura Oncology and Kura Oncology both had 6 articles in the media. Entrada Therapeutics' average media sentiment score of 0.49 beat Kura Oncology's score of -0.62 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TRDA or SDGR?

In the previous week, Entrada Therapeutics had 4 more articles in the media than Schrodinger. MarketBeat recorded 6 mentions for Entrada Therapeutics and 2 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.15 beat Entrada Therapeutics' score of 0.49 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TRDA or ETON?

In the previous week, Entrada Therapeutics had 2 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 6 mentions for Entrada Therapeutics and 4 mentions for Eton Pharmaceuticals. Entrada Therapeutics' average media sentiment score of 0.49 beat Eton Pharmaceuticals' score of 0.20 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Entrada Therapeutics (TRDA) Competitors

$7.00 +0.42 (+6.31%)

As of 02:50 PM Eastern

Compare

TRDA vs. ALVO, KURA, SDGR, PHAT, and ETON

Should you buy Entrada Therapeutics stock or one of its competitors? MarketBeat compares Entrada Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entrada Therapeutics include Alvotech (ALVO), Kura Oncology (KURA), Schrodinger (SDGR), Phathom Pharmaceuticals (PHAT), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.

How does Entrada Therapeutics compare to Alvotech?

Entrada Therapeutics (NASDAQ:TRDA) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

86.4% of Entrada Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 0.5% of Alvotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Entrada Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Alvotech has a net margin of -14.36% compared to Entrada Therapeutics' net margin of -2,895.05%. Alvotech's return on equity of -11.92% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Alvotech	-14.36%	-11.92%	-7.58%

In the previous week, Alvotech had 6 more articles in the media than Entrada Therapeutics. MarketBeat recorded 12 mentions for Alvotech and 6 mentions for Entrada Therapeutics. Alvotech's average media sentiment score of 0.84 beat Entrada Therapeutics' score of 0.49 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entrada Therapeutics presently has a consensus target price of $18.25, indicating a potential upside of 160.90%. Alvotech has a consensus target price of $7.60, indicating a potential upside of 102.94%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Entrada Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alvotech has higher revenue and earnings than Entrada Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.68	-$143.75M	-$3.99	N/A
Alvotech	$588.90M	1.92	$27.92M	-$0.25	N/A

Summary

Alvotech beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Kura Oncology has a net margin of -411.19% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

In the previous week, Kura Oncology and Kura Oncology both had 6 articles in the media. Entrada Therapeutics' average media sentiment score of 0.49 beat Kura Oncology's score of -0.62 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entrada Therapeutics has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.48	-$278.67M	-$3.35	N/A
Entrada Therapeutics	$25.42M	10.68	-$143.75M	-$3.99	N/A

Kura Oncology presently has a consensus price target of $25.58, suggesting a potential upside of 193.22%. Entrada Therapeutics has a consensus price target of $18.25, suggesting a potential upside of 160.90%. Given Kura Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Kura Oncology is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

86.4% of Entrada Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kura Oncology has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

Summary

Kura Oncology and Entrada Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Schrodinger?

Entrada Therapeutics (NASDAQ:TRDA) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

In the previous week, Entrada Therapeutics had 4 more articles in the media than Schrodinger. MarketBeat recorded 6 mentions for Entrada Therapeutics and 2 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.15 beat Entrada Therapeutics' score of 0.49 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 10.1% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Schrodinger has higher revenue and earnings than Entrada Therapeutics. Schrodinger is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.68	-$143.75M	-$3.99	N/A
Schrodinger	$255.87M	4.51	-$103.26M	-$1.41	N/A

Entrada Therapeutics currently has a consensus price target of $18.25, suggesting a potential upside of 160.90%. Schrodinger has a consensus price target of $20.25, suggesting a potential upside of 29.53%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Schrodinger has a net margin of -40.61% compared to Entrada Therapeutics' net margin of -2,895.05%. Schrodinger's return on equity of -30.85% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Schrodinger	-40.61%	-30.85%	-15.32%

Summary

Schrodinger beats Entrada Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Entrada Therapeutics compare to Phathom Pharmaceuticals?

Entrada Therapeutics (NASDAQ:TRDA) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Phathom Pharmaceuticals has a net margin of -76.77% compared to Entrada Therapeutics' net margin of -2,895.05%. Phathom Pharmaceuticals' return on equity of 0.00% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

In the previous week, Entrada Therapeutics had 6 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 6 mentions for Entrada Therapeutics and 0 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.87 beat Entrada Therapeutics' score of 0.49 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
Phathom Pharmaceuticals	Very Positive

Entrada Therapeutics currently has a consensus target price of $18.25, suggesting a potential upside of 160.90%. Phathom Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 155.00%. Given Entrada Therapeutics' higher possible upside, equities research analysts clearly believe Entrada Therapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Entrada Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.68	-$143.75M	-$3.99	N/A
Phathom Pharmaceuticals	$175.11M	4.47	-$221.25M	-$2.12	N/A

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Phathom Pharmaceuticals beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Eton Pharmaceuticals?

Entrada Therapeutics (NASDAQ:TRDA) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Entrada Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Entrada Therapeutics presently has a consensus price target of $18.25, suggesting a potential upside of 160.90%. Eton Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 42.38%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Entrada Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Eton Pharmaceuticals has a net margin of -1.70% compared to Entrada Therapeutics' net margin of -2,895.05%. Eton Pharmaceuticals' return on equity of -5.68% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

In the previous week, Entrada Therapeutics had 2 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 6 mentions for Entrada Therapeutics and 4 mentions for Eton Pharmaceuticals. Entrada Therapeutics' average media sentiment score of 0.49 beat Eton Pharmaceuticals' score of 0.20 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Eton Pharmaceuticals has higher revenue and earnings than Entrada Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.68	-$143.75M	-$3.99	N/A
Eton Pharmaceuticals	$79.95M	9.87	-$4.60M	-$0.07	N/A

Summary

Eton Pharmaceuticals beats Entrada Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRDA vs. The Competition

Export

Metric	Entrada Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$271.35M	$3.33B	$6.42B	$12.48B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-1.75	18.86	23.85	24.39
Price / Sales	10.68	319.25	520.29	116.29
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.87	6.82	10.04	6.74
Net Income	-$143.75M	$24.09M	$3.56B	$337.03M
7 Day Performance	2.57%	-2.69%	-1.09%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-11.79%	48.33%	28.56%	34.29%

Entrada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRDA Entrada Therapeutics	4.1285 of 5 stars	$7.00 +6.3%	$18.25 +160.9%	-20.1%	$271.35M	$25.42M	N/A	110
ALVO Alvotech	3.0805 of 5 stars	$3.42 +2.4%	$7.60 +122.2%	-72.6%	$1.01B	$588.90M	N/A	1,460	News Coverage
KURA Kura Oncology	2.2325 of 5 stars	$10.41 -7.5%	$26.38 +153.4%	+34.8%	$998.71M	$71.64M	N/A	130	News Coverage Analyst Forecast
SDGR Schrodinger	3.2423 of 5 stars	$13.15 -1.1%	$20.25 +54.0%	-34.8%	$981.87M	$254.91M	N/A	790
PHAT Phathom Pharmaceuticals	2.7414 of 5 stars	$11.10 -2.0%	$25.00 +125.2%	+103.8%	$903.64M	$204.89M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRDA) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Competitors

TRDA vs. ALVO, KURA, SDGR, PHAT, and ETON

How does Entrada Therapeutics compare to Alvotech?

Summary

How does Entrada Therapeutics compare to Kura Oncology?

Summary

How does Entrada Therapeutics compare to Schrodinger?

Summary

How does Entrada Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Entrada Therapeutics compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Competitors

TRDA vs. ALVO, KURA, SDGR, PHAT, and ETON

How does Entrada Therapeutics compare to Alvotech?

Do insiders & institutionals believe in TRDA or ALVO?

Which has more volatility and risk, TRDA or ALVO?

Is TRDA or ALVO more profitable?

Does the media refer more to TRDA or ALVO?

Do analysts rate TRDA or ALVO?

Which has stronger earnings & valuation, TRDA or ALVO?

Summary

How does Entrada Therapeutics compare to Kura Oncology?

Is KURA or TRDA more profitable?

Does the media favor KURA or TRDA?

Which has better valuation & earnings, KURA or TRDA?

Do analysts prefer KURA or TRDA?

Do insiders and institutionals hold more shares of KURA or TRDA?

Which has more volatility and risk, KURA or TRDA?

Summary

How does Entrada Therapeutics compare to Schrodinger?

Does the media prefer TRDA or SDGR?

Do institutionals and insiders hold more shares of TRDA or SDGR?

Which has stronger earnings and valuation, TRDA or SDGR?

Do analysts rate TRDA or SDGR?

Which has more risk & volatility, TRDA or SDGR?

Is TRDA or SDGR more profitable?

Summary

How does Entrada Therapeutics compare to Phathom Pharmaceuticals?

Which has more risk and volatility, TRDA or PHAT?

Is TRDA or PHAT more profitable?

Does the media prefer TRDA or PHAT?

Do analysts recommend TRDA or PHAT?

Which has higher earnings & valuation, TRDA or PHAT?

Do insiders & institutionals hold more shares of TRDA or PHAT?

Summary

How does Entrada Therapeutics compare to Eton Pharmaceuticals?

Which has more risk and volatility, TRDA or ETON?

Do analysts rate TRDA or ETON?

Is TRDA or ETON more profitable?

Does the media prefer TRDA or ETON?

Do insiders and institutionals hold more shares of TRDA or ETON?

Which has higher valuation and earnings, TRDA or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools